Lightlake Therapeutics, Inc. Acquires a Patent With the Potential to Establish a New Treatment Paradigm to Terminate …
Lightlake Therapeutics, Inc. Acquires a Patent With the Potential to Establish a New Treatment Paradigm to Terminate …
LONDON — Lightlake Therapeutics Inc has acquired US Patent 5,587,381, entitled: ‘Method for terminating methadone maintenance through extinction of the opiate-taking responses’, using an opioid antagonist as treatment.
Read more on GlobeNewswire… Continue reading
Lightlake Therapeutics Inc. Comments on Unusual Trading Activity
Lightlake Therapeutics Inc. Comments on Unusual Trading Activity
Filed under: treatment for amphetamine addiction
LONDON, Feb 01, 2012 (MARKETWIRE via COMTEX) — Lightlake Therapeutics Inc. /quotes/zigman/572032 LLTP -3.33% (the "Company" or "Lightlake"), an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using …
Source
… Continue reading →